Literature DB >> 8015294

Rat myoblastic sarcoma cell lines. A model for the study of invasion, metastasis, and myogenic differentiation.

F Babaï1, A Royal.   

Abstract

BACKGROUND: To understand the relation between differentiation and metastasis and to identify genes involved in invasive or metastatic potential of cancer cells it is necessary to develop experimental models allowing in vivo and in vitro studies. EXPERIMENTAL
DESIGN: Cell lines with definite metastatic potentials have been established and cloned from a metastatic nodule of an induced rhabdomyosarcoma in syngeneic F344 rats. The parental cell line, SMF-A, is tumorigenic, highly invasive and metastatic. Another cell line, SMF-D, derived from the parental cell line, is also tumorigenic but not metastatic. Biopathologic differences between the metastatic and nonmetastatic SMF cell lines have been studied.
RESULTS: The loss of metastatic potential of the SMF-D cell line was found to be stable and was accompanied by changes in in vitro invasiveness and in myogenic differentiation state. An immunohistochemical study of the expression of cytoskeletal proteins (vimentin, desmin, alpha-actins) indicates that desmin is undetectable in metastatic SMF-A cells, whereas it is strongly expressed in the nonmetastatic SMF-D cells. However, the two cell lines express vimentin but not sarcomeric alpha-actin. These observations suggest that SMF-A cells are of undifferentiated premyoblastic type and SMF-D cells, of myoblastic type. Our study suggests an association between the appearance of myogenic differentiation and the loss of metastatic potential in the SMF-D cell line.
CONCLUSIONS: This rat myoblastic sarcoma model may prove useful for in vivo and in vitro studies of the metastatic potential of tumor cells. This model also lends itself to studies of the relation between invasive or metastatic potential and differentiation since the steps of myogenic differentiation are well known.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8015294

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  In vitro proliferation and in vivo malignancy of cell lines simultaneously derived from a chemically-induced heterogeneous rat mammary tumor.

Authors:  F Tagliaferri; L Teodori; M G Valente; F Stipa; A Cucina; W Göhde; D Colettii; P Alo; S Stipa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-03       Impact factor: 2.416

2.  Selection, establishment and characterization of cell lines derived from a chemically-induced rat mammary heterogeneous tumor, by flow cytometry, transmission electron microscopy, and immunohistochemistry.

Authors:  L Teodori; F Tagliaferri; F Stipa; M G Valente; D Coletti; A Manganelli; M Guglielmi; L S D'Angelo; H Schäfer; W Göhde
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-03       Impact factor: 2.416

3.  Inhibition of tumor invasiveness by 1alpha,25-dihydroxyvitamin D3 coupled to a decline in protein kinase A activity and an increase in cytoskeletal organization.

Authors:  M R Young; Y Lozano
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

4.  Cloning and identification of genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines.

Authors:  L Daigneault; R Beaulieu; M Filion; L Gaboury; A Royal; F Babaï
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

5.  Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602).

Authors:  J A Marchal; C Melguizo; J Prados; A E Aránega; J A Gómez; J Campos; M A Gallo; A Espinosa; N Arena; A Aránega
Journal:  Jpn J Cancer Res       Date:  2000-09

6.  Establishment and characterization of high- and low-lung-metastatic cell lines derived from murine colon adenocarcinoma 26 tumor line.

Authors:  K Sakata; K Kozaki; K Iida; R Tanaka; S Yamagata; K R Utsumi; S Saga; S Shimizu; M Matsuyama
Journal:  Jpn J Cancer Res       Date:  1996-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.